Accelerating access to treatments for rare diseases
暂无分享,去创建一个
Changes in regulatory policy and legislative incentives to promote the development of drugs for rare diseases — orphan drugs — have led to increases in the number of orphan drug designations, but the rate of such products reaching the market remains frustratingly flat. This article highlights areas in which novel approaches could facilitate regulatory approval and access to treatments for rare diseases.
[1] Martin Možina,et al. European regulation on orphan medicinal products: 10 years of experience and future perspectives. , 2011, Nature reviews. Drug discovery.
[2] Timothy R. Coté,et al. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years , 2010, Nature Reviews Drug Discovery.